Athira Pharma Inc (ATHA) - Net Assets
Based on the latest financial reports, Athira Pharma Inc (ATHA) has net assets worth $27.79 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($92.15 Million) and total liabilities ($64.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ATHA financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $27.79 Million |
| % of Total Assets | 30.16% |
| Annual Growth Rate | N/A |
| 5-Year Change | -91.34% |
| 10-Year Change | N/A |
| Growth Volatility | 27.41 |
Athira Pharma Inc - Net Assets Trend (2018–2025)
This chart illustrates how Athira Pharma Inc's net assets have evolved over time, based on quarterly financial data. Also explore ATHA asset base for the complete picture of this company's asset base.
Annual Net Assets for Athira Pharma Inc (2018–2025)
The table below shows the annual net assets of Athira Pharma Inc from 2018 to 2025. For live valuation and market cap data, see how much is Athira Pharma Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $27.79 Million | -38.03% |
| 2024-12-31 | $44.84 Million | -65.56% |
| 2023-12-31 | $130.19 Million | -44.63% |
| 2022-12-31 | $235.14 Million | -26.77% |
| 2021-12-31 | $321.08 Million | +17.06% |
| 2020-12-31 | $274.28 Million | +1490.67% |
| 2019-12-31 | $-19.72 Million | -32.48% |
| 2018-12-31 | $-14.89 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Athira Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 49582900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Comprehensive Income | $-4.00K | -0.01% |
| Other Components | $539.55 Million | 1941.52% |
| Total Equity | $27.79 Million | 100.00% |
Athira Pharma Inc Competitors by Market Cap
The table below lists competitors of Athira Pharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
OSK Ventures International Bhd
KLSE:0053
|
$26.63 Million |
|
Newtree Co.Ltd
KQ:270870
|
$26.64 Million |
|
PlumbFast Co. Ltd
KQ:035200
|
$26.64 Million |
|
Embrace Change Acquisition Corp Ordinary Shares
NASDAQ:EMCG
|
$26.65 Million |
|
ERREDUE S.P.A.
F:Z9H
|
$26.62 Million |
|
Worth Peripherals Limited
NSE:WORTH
|
$26.62 Million |
|
Carimin Petroleum Bhd
KLSE:5257
|
$26.61 Million |
|
Starteck Finance Limited
NSE:STARTECK
|
$26.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Athira Pharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 44,841,000 to 27,790,000, a change of -17,051,000 (-38.0%).
- Net loss of 105,609,000 reduced equity.
- Other comprehensive income decreased equity by 5,000.
- Other factors increased equity by 88,563,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-105.61 Million | -380.03% |
| Other Comprehensive Income | $-5.00K | -0.02% |
| Other Changes | $88.56 Million | +318.69% |
| Total Change | $- | -38.03% |
Book Value vs Market Value Analysis
This analysis compares Athira Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.18x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-4.56 | $7.66 | x |
| 2019-12-31 | $-6.05 | $7.66 | x |
| 2020-12-31 | $84.43 | $7.66 | x |
| 2021-12-31 | $86.96 | $7.66 | x |
| 2022-12-31 | $62.32 | $7.66 | x |
| 2023-12-31 | $34.24 | $7.66 | x |
| 2024-12-31 | $11.65 | $7.66 | x |
| 2025-12-31 | $6.50 | $7.66 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Athira Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -380.03%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 3.32x
- Recent ROE (-380.03%) is below the historical average (-93.95%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.61 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.19 Million |
| 2020 | -7.28% | 0.00% | 0.00x | 1.02x | $-47.38 Million |
| 2021 | -17.08% | 0.00% | 0.00x | 1.03x | $-86.96 Million |
| 2022 | -40.67% | 0.00% | 0.00x | 1.10x | $-119.15 Million |
| 2023 | -90.39% | 0.00% | 0.00x | 1.23x | $-130.69 Million |
| 2024 | -216.19% | 0.00% | 0.00x | 1.31x | $-101.42 Million |
| 2025 | -380.03% | 0.00% | 0.00x | 3.32x | $-108.39 Million |
Industry Comparison
This section compares Athira Pharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Athira Pharma Inc (ATHA) | $27.79 Million | 0.00% | 2.32x | $26.62 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Athira Pharma Inc
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds… Read more